Ipsen rises on FDA breakthrough therapy status for blood cancer therapy
Source: SeekingAlpha
2026-01-14 06:57:07 ET
More on Ipsen S.A.
- Ipsen S.A. (IPSEY) Q3 2025 Earnings Call Transcript
- Ipsen S.A. 2025 Q3 - Results - Earnings Call Presentation
- Ipsen S.A. reports Q3 results; upgrades FY outlook
- Seeking Alpha’s Quant Rating on Ipsen S.A.
- Historical earnings data for Ipsen S.A.
Read the full article on Seeking Alpha
For further details see:
Ipsen rises on FDA breakthrough therapy status for blood cancer therapy
Ipsen ADR
NASDAQ: IPSEY
IPSEY Trading
0.0% G/L:
$46.145 Last:
720 Volume:
$46.145 Open:
IPSEY Latest News
December 07, 2025 05:33:00 pm
ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025
December 05, 2025 05:00:00 am
ImCheck Announces Oral Presentation of ICT01 First-Line AML Data at the 67th ASH Annual Meeting
June 02, 2025 08:00:00 am
PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer
